{"slideshow_credits": null, "snippet": "Our high-tech process of pharmaceutical research is broken \u2014 and the solution might be old-fashioned trial and error.", "abstract": "Most drug companies have continued to devote vast majority of their funding to target-based research, informed by genomics, despite fact that more traditional methods of drug discovery like trial-and-error have proved more productive; example of trial-and-error method yielding positive result is research that chemical engineer Todd Zion has done on developing better form of insulin, promise of which has led Merck to acquire Zion's company SmartCells.", "section_name": "Magazine", "print_page": "61", "document_type": "article", "byline": {"person": [{"firstname": "Dan", "role": "reported", "lastname": "HURLEY", "rank": 1, "organization": ""}], "original": "By DAN HURLEY", "contributor": ""}, "web_url": "http://www.nytimes.com/2014/11/16/magazine/why-are-there-so-few-new-drugs-invented-today.html", "lead_paragraph": "Our high-tech process of pharmaceutical research is broken \u2014 and the solution might be old-fashioned trial and error.", "headline": {"main": "Why Are So Few Blockbuster Drugs Invented Today?", "print_headline": "Kemia Malekvilibro Chemical Imbalance", "content_kicker": "The Innovations Issue"}, "_id": "546480e238f0d82df864ff5d", "word_count": "2742", "multimedia": [{"height": 126, "url": "images/2014/11/11/magazine/16insulin1/mag-16insulin-t-thumbWide.jpg", "legacy": {"wideheight": "126", "wide": "images/2014/11/11/magazine/16insulin1/mag-16insulin-t-thumbWide.jpg", "widewidth": "190"}, "subtype": "wide", "width": 190, "type": "image"}, {"height": 400, "url": "images/2014/11/11/magazine/16insulin1/mag-16insulin-t-articleLarge.jpg", "legacy": {"xlarge": "images/2014/11/11/magazine/16insulin1/mag-16insulin-t-articleLarge.jpg", "xlargewidth": "600", "xlargeheight": "400"}, "subtype": "xlarge", "width": 600, "type": "image"}, {"height": 75, "url": "images/2014/11/11/magazine/16insulin1/mag-16insulin-t-thumbStandard.jpg", "legacy": {"thumbnail": "images/2014/11/11/magazine/16insulin1/mag-16insulin-t-thumbStandard.jpg", "thumbnailwidth": "75", "thumbnailheight": "75"}, "subtype": "thumbnail", "width": 75, "type": "image"}], "pub_date": "2014-11-16T00:00:00Z", "source": "The New York Times", "news_desk": "Magazine", "keywords": [{"value": "Drugs (Pharmaceuticals)", "name": "subject", "is_major": "Y", "rank": "1"}, {"value": "Insulin", "name": "subject", "is_major": "Y", "rank": "2"}, {"value": "Zion, Todd C", "name": "persons", "is_major": "Y", "rank": "3"}, {"value": "SmartCells", "name": "organizations", "is_major": "Y", "rank": "4"}, {"value": "Merck & Company Inc", "name": "organizations", "is_major": "Y", "rank": "5"}, {"value": "Research", "name": "subject", "is_major": "N", "rank": "6"}, {"value": "Genetics and Heredity", "name": "subject", "is_major": "N", "rank": "7"}, {"value": "Science and Technology", "name": "subject", "is_major": "N", "rank": "8"}, {"value": "Massachusetts Institute of Technology", "name": "organizations", "is_major": "N", "rank": "9"}], "blog": [], "subsection_name": null, "type_of_material": "News"}